Ritonavir Completed Phase 1 Trials for Human Immunodeficiency Virus (HIV) Infections Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03234036A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir
NCT01802918Single Dose Escalation Study of GSK2838232 in Healthy Subjects
NCT02289495A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects
NCT02795754Single and Repeated Dose Escalation Study of GSK2838232
NCT00326716Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
NCT00001766Drug Interactions Among Anti-HIV Agents
NCT02489487Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500
NCT00307502Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV
NCT00665951Pharmacokinetic Study of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)
NCT00977301Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)
NCT01638650A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
NCT00135434Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism
NCT01047995Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects
NCT01073761Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study
NCT00344123Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects
NCT01374802Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers
NCT00435929A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
NCT00001108A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses
NCT00001133Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir
NCT00001091Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
NCT00000822A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
NCT00000906Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients
NCT00000952A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
NCT00000941A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood
NCT00000902A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment
NCT00063804Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
NCT00038480Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants
NCT00004580A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
NCT01896622The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers
NCT00767117TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.
NCT00765271Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects